Shee	et <u>1</u> of _	4
------	------------------	---

			
Substitute Form PTO-1449 (Modified)	U.S. D partment of Commerce Patent and Trademark Office	Attorney's Dock t No. 07763-048001	Application No. 09/508,208
1	cl sure Statement oplicant	Applicant Abraham Pinter	8407
(Us several si	neets if necessary)	Filing Date March 8, 2000	Group Art Unit

			U.S. Pate	ent Documents			ם ב
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
$h\Lambda$	AA	5,336,603	8/9/94	Capon et al.	435	69.7	
110	AB			·			
	AC						
	AD						
	AE						
	AF						
	· AG						
	AH						
	AI		·				
	AJ						
	AK		·				

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or	01	Outstand		slation
Initial	ID AL	Number	Date	Patent Office	Class	Subclass	Yes	∵No≝
	AM	 						
	AN		· .					
	AO					·		
	AP			. ,				

	Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.			
Injtial	ID	Document		
pa	AQ	Ashkenazi et al., "Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4" Proc. Nat'l. Acad. Sci. USA 88:7056-7060, 1991.		
	AR	Bebbington et al., "High-level expression of a recombinant antibody from myeloma cells using a glutabmine"Bio/Technology 10:169-175, 1992.		
	AS	Bou-Habib et al., "Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency" J. of Virol. 68(9):6006-6013, 1994.		
4	AT	Burton et al., "Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody" Science 266:1024-1027, 1994.		

Examiner Signature	Dat Considered 3/2-7/3
EXAMINER: Initials-citation considered. Draw line through citation if no next communication to applicant.	
	Substitute Disclosur Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07763-048001	Application No. 09/508,208
	l sure Stat ment plicant	Applicant Abraham Pinter	
(Us several sheets if necessary) (37 CFR §1.98(b))		Filing Date March 8, 2000	Gr up Art Unit

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig. ID	Document
Initial	AU	Chamat et al., "Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals" J. of Immun. 149(2):649-654, 1992.
	AV	Conley et al., "Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly anti-V3" J. of Virol. 68(11):6994-7000, 1994.
	AW	Conley et al., "Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates" Proc. Nat'l. Acad. Sci. USA 91:3348-3352, 1994.
	AX	Cordell et al., "Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1" Virology 185:72-79, 1991.
·	AY	D'Souza et al., "Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies" AIDS 9(8):867-874, 1995.
	AZ	D'Souza at al., "Evaluation of monoclonal antibodies to HIV-1 envelope by netralization and binding assays:"AIDS 8(2):169-181, 1994.
	AAA	Fouts et al., "Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal" J. of Virol. 71(4):2779-2785, 1997.
	ABB	Fishwald et al., "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice" Nature Biotechnology 14:845-851, 1996.
	ACC	Fung et al., "Identification and characterization of a neutralization site within the second variable region of human" J. of Virology 66(2):848-856, 1992.
	ADD	Gao et al., "Genetic variation of HIV type 1 in four world health organization-sponsored vaccine evaluation sites:" AIDS Research and Human Retroviruses 10(11):1359-1368, 1994.
	AEE	Golding et al., "Neutralization of HIV-1" AIDS Res. And Human Retroviruses 10(6):633-643, 1994.
	AFF	Gomatos et al., "Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-tropic" J. of Immunol. 144(11):4183-4188, 1990.
	AGG	Guo et al., "HIV acquires functional adhesion receptors from host cells" AIDS Res. And Human Retroviruses 11(9):1007-1013, 1995.
	АНН	Hanson, C., "Measuring vaccine-induced HIV neutralization: Report of a workshop" AIDS Res. And Human Retroviruses 10(6):645-648, 1994.
·	AII	Hildreth et al., "Involvement of a leukocyte adhesion recepotr (LFA-1) in HIV-induced syncytium formation" Science 244:1017-1116, 1989.
	AJJ	Ho et al., "Another discontinues epitope on glycoprotein gp120 that is important in human immunodeficiency" Proc. Nat'l. Acad. Sci. USA 88:8949-8952, 1991.
	AKK	Ho et al., "Conformational epitope on gp120 important in CD4 binding and human immunodeficiency" J. of Virol. 65(1):489-493, 1991.
	ALL	Kayman et al., "Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency" J. of Virol. 68(1):400-410, 1994.
	AMM	Lee et al., "Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex" J. of Virol. 71(8):6037-6043, 1997.
	ANN	Mascola, J., "Neutralizing antibody activity in sera from human immunodeficiency virus type 1 vaccine recipients"AIDS Res. And Human Retroviruses 10(2):S55, 1994.
	AOO	Matthews, T., "Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development" AIDS Res. And Human Retroviruses 10(6):631-632, 1994.
d	APP	McKeating et al., "Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent" J. of Virol. 67(8):4932-4944, 1993.

Examiner Signature	Dat Considered	
	3/23/05	
EXAMINER:Initials citation considered. Draw lin	through citation if not in conformance and not considered. Include copy of this f rm with	_
port communication to applicant		

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Pat nt and Trademark Office	Attorney's Dock t No. 07763-048001	Application No. 09/508,208
Information Disclosure Statement by Applicant (Us several sheets if necessary) (37 CFR §1.98(b))		Applicant Abraham Pinter	
		Filing Date March 8, 2000	Gr up Art Unit

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID	Document
ha	AQQ	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice" Nature Genetics 15:146-156, 1997.
1 0	ARR	Moore et al., "Primary isolates of human immunodeficiency virus type 1 are relatively resistanct to neutralization" J. of Virol. 69(1):101-109, 1995.
	ASS	Moore et al., "Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of" J. of Virol. 67(2):863-875, 1993.
	ATT	Moore et al., "Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120" J. of Virol. 67(10):6136-6151, 1993.
	AUU	Muster et al., "Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced" J. of Virol. 68(6):4031-4034, 1994.
	AVV	Olshevsky et al., "Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding" J. of Virol. 64(12):5701-5707, 1990.
	AWW	Pincus et al., "Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers" J. of Clin. Invest. 93:2505-2513, 1994.
	AXX	Sawyer et al., "Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell" J. of Virol. 68(3):1342-1349, 1994.
	AYY	Schutten et al., "Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies" Scand. J. Immunol. 41:18-22, 1995.
	AZZ	Stamatatos et al., "Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency" Virology 229:360-369, 1997.
	AAAA	Sullivan et al., "Effect of animo acid changes in the V!/V2 region of the human immunodeficiency virus type 1 gp120" J. of Virol. 67(6):3674-3679, 1993.
	ABBB	Thali et al., "Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency" J. of Virol. 66(9):5635-5641, 1992.
	ACCC	Tilley et al., "Human and chimpanzee monoclonal antibodies with antiviral activity against HIV-1" AIDS Research Review 3:255-287, 1993.
	ADDD	Trkola et al., "Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal" J. o f Virol. 69(11):6609-6617, 1995.
	AEEE	Trkola et al., "Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of" J. of Virol. 70(2):1100-1108, 1996.
	AFFF	VanCott et al., "Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein" J. of Immunol. 155(8):4100-4110, 1995.
	AGGG	Vancott et al., "Differential role of V3-Specific antibodies in neutralization assays involving primary and laboratory-adapted" AIDS Res. And Human Retroviruses 11(11):1379-1391, 1995.
	АННН	Vijh-Warrier, et al., "Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody" J. of Virol. 70(7):4466-4473, 1996.
	AIII	Wang et al., "Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1:" J. of Virol. 69(4):2708-2715, 1995.
	AJJJ	Warrier et al., "A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus 1 gp120" J. of Virol. 68(7):4636-4642, 1994.
	AKKK	Westervelt et al., "Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo" J. of Virol. 66(4):2577-2582, 1992.

Examiner Signature	Date Considered 3/23/83
EXAMINER: Initials citation considered. Draw line through citation if next communication to applicant.	ot in conformance and not considered. Includ copy of this form with

Substitut Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office		Application No. 09/508,208	
	cl sure Stat ment	Applicant Abraham Pinter		
(Us sev raish	eets if necessary)	Filing Date Group Art Unit March 8, 2000		

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.		
Injtial	ID	Document	
W	ALLL	Wu et al., "Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120:" J. o f Virol. 69(4):2271-2278, 1995.	

Examiner Signature

Dat Considered

Dat Considered

Annual Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not consider d. Include copy of this form with next communication to applicant.